

Virafly®

Favipiravir
Tablet

Description

Virafly® is a prodrug that is metabolized to its active form, ribofuranosyl triphosphate (favipiravir RTP) and that favipiravir RTP selectively inhibits RNA polymerase involved in influenza viral replication.

Indication

Virafly® is indicated for the treatment of novel or re-emerging pandemic influenza virus infections (limited to cases in which other influenza antiviral drugs are ineffective or not sufficiently effective).

Dosage & Administration

The usual dosage of favipiravir for adults is 1600 mg orally twice daily for 1 day followed by 600 mg orally twice daily for 4 days. The total administration period should be 5 days.

Side Effects

Favipiravir has never been administered with the approved dosage. In Japanese clinical studies and the global phase III study, major adverse reactions were increase of blood uric acid, diarrhea, decrease of neutrophil, an increase of AST (GOT) and increase of ALT (GPT).

Contraindications

Favipiravir is contraindicated in Women known or suspected to be pregnant (Early embryonic deaths and teratogenicity have been observed in animal studies) and patients with a history of hypersensitivity to any ingredient of the drug.

Warnings and Precautions

Favipiravir is a drug the use of which is

considered only when there is an outbreak of novel or re-emerging influenza virus infections in which other anti-influenza virus agents are not effective or insufficiently effective, and the government decides to use the drug as a countermeasure against such influenza viruses. When administering the drug, obtain the latest information including government's direction of countermeasures against such influenza viruses, and prescribe only to appropriate patients.

Favipiravir should be administered with care in patients with gout or a history of gout, and patients with hyperuricaemia (Blood uric acid level may increase, and symptoms may be aggravated).

Use in Specific Populations

Pregnancy & Lactation: Do not administer favipiravir to women known or suspected to be pregnant. When administering favipiravir to lactating women, instruct to stop lactating.

Elderly: Since the elderly often have reduced physiological functions, favipiravir should be administered with care to them by monitoring their general conditions.

Pediatric: Favipiravir has not been administered to children.

Overdose

Symptoms of overdose include reduction of body weight, vomiting, Pale yellow nails, decrease hemoglobin level and reduction of locomotor activity.

Pharmaceutical Precautions

Keep in a dry place & store below 30° C. Protect from light & keep out of the reach of children.

Commercial Pack

Virafly® Tablet: Each box containing 10 tablets in 1 x 10's blister strip. Each film coated tablet contains Favipiravir INN 200 mg.



Manufactured by

BEXIMCO PHARMACEUTICALS LTD.

126, Kathaldia, Auchpara, Tongi, Gazipur, Bangladesh
302007966 070420

© Virafly is a registered trademark of Beximco Pharmaceuticals Ltd.

105 mm x 148 mm FS

105 mm x 148 mm FS

